Tiziana Life Sciences Ltd Com Stock Price, News & Analysis

Tiziana Life Sciences (TLSA) announced positive results from a study combining nasal anti-CD3 (foralumab) with semaglutide (Ozempic). The research, conducted at Brigham and Women's Hospital, demonstrated that the combination improves liver homeostasis and reduces inflammation in diet-induced obesity models. Key findings show synergistic effects in promoting liver health, with the combination therapy resulting in significant reductions in pro-inflammatory cytokines and improvements in liver markers associated with metabolic regulation. The study suggests this novel approach could effectively combat obesity-related inflammation and liver dysfunction.

Tiziana Life Sciences (NASDAQ: TLSA) has announced a $4 million grant from the National Institutes of Health to study intranasal anti-CD3 for Alzheimer's disease treatment. The grant, awarded to Dr. Howard Weiner at Brigham and Women's Hospital, will fund preclinical and clinical studies over several years. Tiziana's proprietary anti-CD3 formulation, administered intranasally, aims to modulate immune system activity and reduce neuroinflammation in Alzheimer's patients. This funding supports Tiziana's broader strategy to explore anti-CD3 in various autoimmune and inflammatory diseases. The company plans to initiate first-in-human clinical trials for Alzheimer's Disease in the coming months, marking a significant step towards potential regulatory approval and commercialization.

Tiziana Life Sciences (Nasdaq: TLSA) has appointed Ivor Elrifi as its new Chief Executive Officer, effective immediately. Elrifi, formerly the global head of the Patent Group at Cooley, brings extensive experience in intellectual property strategies and business development in the biotech and pharma sectors. Tiziana, focused on developing immunomodulation therapies, aims to accelerate its clinical trials for intranasal foralumab in treating non-active Secondary Progressive Multiple Sclerosis, Alzheimer's Disease, and ALS under Elrifi's leadership.

Gabriele Cerrone, Founder and Executive Chairman, expressed confidence in Elrifi's ability to create substantial value for the company. Elrifi's background includes guiding clients in strategic transactions and M&A involving major pharmaceutical companies. He succeeds Cerrone, who will continue as Executive Chairman, focusing on advancing Tiziana's scientific agenda.

Tiziana Life Sciences (TLSA) has regained compliance with Nasdaq's minimum bid price rule, ensuring its continued listing on the Nasdaq Capital Market. The company, which develops immunomodulation therapies, had been notified of non-compliance on July 19, 2023, when its stock failed to maintain a closing bid price of $1.00 or more for 30 consecutive business days. Tiziana successfully met the requirement by maintaining a minimum closing bid price of $1.00 or more for at least ten consecutive trading days, achieving this on August 9, 2024. As a result, the previously scheduled hearing before the Hearings Panel has been cancelled, and Tiziana's securities will continue to be listed and traded on Nasdaq.

Tiziana Life Sciences (NASDAQ: TLSA) has received FDA Fast Track designation for its intranasal foralumab, a fully human anti-CD3 monoclonal antibody, to treat non-active Secondary Progressive Multiple Sclerosis (na-SPMS). This designation expedites the review process and increases FDA interaction. Intranasal foralumab aims to modulate the immune system and reduce neuroinflammation in neurodegenerative diseases.

The company is currently conducting a Phase 2a trial for na-SPMS and has an Expanded Access Program showing promising results. However, Tiziana faces a potential Nasdaq delisting due to not maintaining a minimum bid price of $1.00. The company plans to appeal this decision and present its compliance plan to the Nasdaq Hearings Panel.

Tiziana Life Sciences (Nasdaq: TLSA) has secured $3.4 million in non-dilutive funding. This funding will support their ongoing Phase 2 trial for intranasal foralumab in treating non-active secondary progressive multiple sclerosis (na-SPMS) and advancements in Alzheimer's Disease research. Chairman and acting CEO, Gabriele Cerrone, emphasized the importance of this funding in propelling their research and expressed their intention to seek further non-dilutive funding.

Tiziana Life Sciences (Nasdaq: TLSA) announced that the FDA has granted approval for the use of intranasal foralumab in treating a patient with moderate Alzheimer's disease under an Expanded Access IND. This pathway allows patients with serious conditions, lacking other therapy options, to access investigational drugs. Dr. Howard L. Weiner, Principal Investigator and Chairman of Tiziana’s Scientific Advisory Board, expressed optimism about the potential of nasal foralumab to slow cognitive decline, citing its effectiveness in reducing microglial inflammation in progressive MS patients. The company plans to closely monitor treatment responses while preparing for a Phase 2 study targeting early symptomatic Alzheimer’s disease. Gabriele Cerrone, Chairman and acting CEO, emphasized the groundbreaking potential of foralumab in addressing neuroinflammation caused by toxic protein accumulation in the brain.

Tiziana Life Sciences (Nasdaq: TLSA) announced that the FDA has accepted its submission for Fast Track Designation for its intranasal foralumab treatment for non-active, secondary-progressive multiple sclerosis (na-SPMS). Foralumab is a fully human anti-CD3 monoclonal antibody designed to induce T regulatory cells. In an Intermediate-Sized Patient Population Expanded Access program, 70% of the ten dosed patients demonstrated a clinically meaningful reduction in fatigue, with disease stability observed over six months. The Fast Track submission included data from both animal models and clinical experience. If granted, this designation could expedite FDA review processes, which is significant given the lack of approved therapies for na-SPMS. Chairman and acting CEO Gabriele Cerrone highlighted the potential of Fast Track Designation to enhance development through increased FDA interaction and partnership.

Tiziana Life Sciences (NASDAQ: TLSA) reported a 80% qualitative improvement in PET imaging for non-active Secondary Progressive Multiple Sclerosis (na-SPMS) patients receiving intranasal foralumab for at least six months. The FDA has permitted the enrollment of an additional 20 patients in the Expanded Access Program (EA), aiming to gather more data and analyze for further insights. The company also applied for FDA Orphan Drug Designation for foralumab to treat na-SPMS. This development is a significant milestone for Tiziana's immunomodulation therapies, as stated by Gabriele Cerrone, the acting CEO and founder.